Eptinezumab

Eptinezumab is a humanized monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its interaction with the receptor. Eptinezumab can be used in the study of preventing migraines[1][2].

Product Specifications

CAS Number

[1644539-04-7]

Product Name Alternative

ALD-403

UNSPSC

12352203

Target

CGRP Receptor

Type

Inhibitory Antibodies

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/eptinezumab.html

Purity

99.90

Solubility

H2O

Smiles

[Eptinezumab]

Molecular Weight

(143.36 kDa)

References & Citations

[1]Dhillon S. Eptinezumab: First Approval. Drugs. 2020;80 (7) :733-739.|[2]LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD) : National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Eptinezumab. 2021 Jul 9.